KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $6.0 million.

  • Fulgent Genetics' Capital Expenditures fell 6903.31% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year decrease of 4608.88%. This contributed to the annual value of $40.3 million for FY2024, which is 8154.19% up from last year.
  • According to the latest figures from Q3 2025, Fulgent Genetics' Capital Expenditures is $6.0 million, which was down 6903.31% from $6.8 million recorded in Q2 2025.
  • Fulgent Genetics' Capital Expenditures' 5-year high stood at $19.5 million during Q3 2024, with a 5-year trough of $2.0 million in Q1 2023.
  • For the 5-year period, Fulgent Genetics' Capital Expenditures averaged around $6.5 million, with its median value being $4.9 million (2023).
  • Examining YoY changes over the last 5 years, Fulgent Genetics' Capital Expenditures showed a top increase of 134371.86% in 2021 and a maximum decrease of 7485.5% in 2021.
  • Fulgent Genetics' Capital Expenditures (Quarter) stood at $6.0 million in 2021, then decreased by 21.08% to $4.7 million in 2022, then plummeted by 34.22% to $3.1 million in 2023, then grew by 21.64% to $3.8 million in 2024, then soared by 60.14% to $6.0 million in 2025.
  • Its Capital Expenditures was $6.0 million in Q3 2025, compared to $6.8 million in Q2 2025 and $4.7 million in Q1 2025.